CD44 and neoplasm: In addition to checkpoint inhibitors, other immune stimulating agents such as interleukins (e.g., IL-2, IL-12) or tumor necrosis factor-alpha (TNF alpha) have been incorporated into the CD44-targeted nanocarriers to boost T-cell activation and attraction of immune effector cells to the tumor site (109–112).